Pyridine Azaspiro M4 Modulators for Lower-Side-Effect Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for M4-mediated diseases such as schizophrenia, Alzheimer's disease, and Parkinson's disease provide modest improvement with significant dose-limiting adverse effects, leading to partial responsiveness and non-compliance.
Innovation Solution
Development of pyridine azaspiro compounds that act as agonists or modulators of the muscarinic M4 receptor, offering a novel approach to treat these diseases by targeting the M4 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological treatments are used for M4-mediated diseases, then some improvement in behavior and cognitive function is achieved, but dose-limiting adverse effects occur leading to partial responsiveness and non-compliance
Solution Approach 1:
The patent applies parameter changes by developing novel pyridine azaspiro compound structures with specific molecular configurations (Formula I) that modify the pharmacological parameters of M4 receptor interaction. The structural variations in R1-R7 substituents and ring systems allow optimization of receptor binding affinity and selectivity, achieving therapeutic effects at lower doses with reduced adverse effects compared to existing treatments
2Reliability
If higher doses of current treatments are administered to overcome partial responsiveness, then therapeutic improvement increases, but adverse effects become more severe
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups and substituent patterns (R1-R7) that target particular aspects of M4 receptor activation. The localized structural features enhance binding to specific receptor subregions, improving therapeutic response while minimizing activation of off-target pathways that cause side effects
3Adaptability or versatility
If non-selective muscarinic agonists are used, then broad cholinergic effects are achieved, but lack of M4 subtype specificity results in increased adverse effects
Solution Approach 1:
The patent applies local quality by incorporating specific structural features in the pyridine azaspiro core and substituent patterns that confer M4 subtype selectivity. The localized molecular characteristics enable preferential binding to M4 receptors over other muscarinic subtypes (M1-M3, M5), achieving targeted cholinergic modulation with reduced adverse effects
Solution Approach 2:
The patent applies asymmetry through the non-symmetric pyridine azaspiro molecular structure with chiral centers and asymmetric substituent arrangements. This asymmetric configuration provides stereoselective interaction with the M4 receptor binding site, enhancing subtype specificity and reducing off-target effects
Data Source
AI summary
The present disclosure provides compounds of Formula I: (I), or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.